Dr. Tagawa on the growing role of radiopharmaceuticals in prostate cancer

Video

“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.

In this video, Scott T. Tagawa, MD, MS, FACP, discusses ongoing and upcoming innovation in the radiopharmaceutical space for treatment of prostate cancer, as well as considerations for physicians who are administering these therapies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.

Related Videos
Phillip H. Kuo, MD, PhD, FACR, answers a question during a Zoom video interview
blurred image of a clinic hallway
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Man talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Dr. Brian F. Chapin in an interview with Urology Times
Dr. Brian F. Chapin in an interview with Urology Times
Brian F. Chapin, MD, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.